Function-Oriented Synthesis: Biological Evaluation of Laulimalide Analogues Derived from a Last Step Cross Metathesis Diversification Strategy

详细信息    查看全文

• 作者：Susan L. Mooberry ; Michael K. Hilinski ; Erin A. Clark ; Paul A. Wender
• 刊名：Molecular Pharmaceutics
• 出版年：2008
• 出版时间：October 6, 2008
• 年：2008
• 卷：5
• 期：5
• 页码：829-838
• 全文大小：301K
• 年卷期：v.5,no.5(October 6, 2008)
• ISSN：1543-8392

文摘

Laulimalide is a potent microtubule stabilizing agent and a promising anticancer therapeutic lead. The identification of stable, efficacious and accessible analogues is critical to clinically exploiting this novel lead. To determine which structural features of laulimalide are required for beneficial function and thus for accessing superior clinical candidates, a series of side chain analogues were prepared through a last step cross metathesis diversification strategy and their biological activities were evaluated. Five analogues, differing in potency from 233 nM to 7.9 μM, effectively inhibit cancer cell proliferation. Like laulimalide, they retain activity against multidrug resistant cells, stabilize microtubules and cause the formation of aberrant mitotic spindles, mitotic accumulation, Bcl-2 phosphorylation and initiation of apoptosis. Structural modifications in the C₂₃−C₂₇ dihydropyran side chain can be made without changing the overall mechanism of action, but it is clear that this subunit has more than a bystander role.